Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts
- 1 October 1998
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 36 (10) , 2950-2956
- https://doi.org/10.1128/jcm.36.10.2950-2956.1998
Abstract
The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 against 83 isolates of Acremonium strictum,Aspergillus flavus, Aspergillus fumigatus,Aspergillus terreus, Bipolaris spp.,Blastomyces dermatitidis, Cladophialophora bantiana, Fusarium oxysporum, Fusarium solani, Histoplasma capsulatum,Phialophora spp., Pseudallescheria boydii,Rhizopus arrhizus, Scedosporium prolificans, and Sporothrix schenckii were compared. The in vitro activities of these agents against 104 isolates of yeast pathogens ofCandida spp., Cryptococcus neoformans, andTrichosporon beigelii were also compared. MICs were determined by following a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NCCLS) for broth microdilution testing of the filamentous fungi (visual MICs) and the NCCLS M27-A broth microdilution method for yeasts (both visual and turbidimetric MICs). The in vitro fungicidal activity of SCH56592 was superior (minimum fungicidal concentrations [MFCs], 0.25 to 4 μg/ml for 7 of 18 species tested) to those of MK-0991 and LY303366 (MFCs, 8 to >16 μg/ml for all species tested) for the molds tested, but the echinocandins had a broader spectrum of fungicidal activity (MFCs at which 90% of strains are inhibited [MFC90s], 0.5 to 4 μg/ml for 6 of 9 species tested) than SCH56592 (MFC90s, 0.25 to 8 μg/ml for 4 of 9 species tested) against most of the yeasts tested. Neither echinocandin had in vitro activity (MICs, >16 μg/ml) against C. neoformans and T. beigelii, while the SCH56592 MICs ranged from 0.12 to 1.0 μg/ml for these two species. The MICs of the three agents for the other species ranged from <0.03 to 4 μg/ml. These results suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined.Keywords
This publication has 37 references indexed in Scilit:
- Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive CandidiasisAntimicrobial Agents and Chemotherapy, 1998
- In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)Antimicrobial Agents and Chemotherapy, 1997
- The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceThe American Journal of Medicine, 1996
- Epidemiology of Nosocomial Fungal Infections, with Emphasis on Candida SpeciesClinical Infectious Diseases, 1995
- Fungemia in Children Infected with the Human Immunodeficiency Virus: New Epidemiologic Patterns, Emerging Pathogens, and Improved Outcome with Antifungal TherapyClinical Infectious Diseases, 1995
- Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungiAntimicrobial Agents and Chemotherapy, 1995
- Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthaseAntimicrobial Agents and Chemotherapy, 1994
- The Spectrum of Non-Candida Fungal Infections following Bone Marrow TransplantationMedicine, 1993
- Candidemia in a Tertiary Care Hospital: Epidemiology, Risk Factors, and Predictors of MortalityClinical Infectious Diseases, 1992
- Opportunistic Mycoses in the Immunocompromised Host: Experience at a Cancer Center and ReviewClinical Infectious Diseases, 1992